Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research report sent to investors on Monday, Benzinga reports. The firm currently has a $50.00 price target on the stock. A number of other brokerages also recently issued reports on CRNX. Robert W. Baird upped their price target […]
More Stories
Asking Rents Decline in November: Zillow
By Naveen Athrappully Home rents across the United States edged down in November, in line with a slowdown usually seen...
US Department of State Issues Travel Advisory Against 2 Middle Eastern Countries
By Naveen Athrappully The U.S. Department of State renewed its travel advisory for two Middle Eastern nations—Yemen and Jordan—last week...
Paramount Updates Warner Bros. Offer, Affirms Ellison Family Backing
By Andrew Moran Paramount Skydance amended its offer to buy Warner Bros. Discovery on Dec. 22, guaranteeing backing from Oracle...
Japan to Resume Operations at World’s Largest Nuclear Plant 15 Years After Fukushima Disaster
By Rachel Roberts Japan is set to resume operations at the world’s largest nuclear power plant, marking a key development...
Who is Yeonjun? Band, Age, Albums, and Updates
One of the eldest and all-around band members of TXT (TOMORROW X TOGETHER), Yeonjun. He is the only member born...
Skip the Spa: Achieving Relaxation with a Backyard Sauna Kit
A luxurious spa visit is no longer necessary for those seeking a tranquil and calming environment for relaxation. Many homeowners...